Alzheimer's research & therapy
-
Alzheimers Res Ther · Jan 2016
Randomized Controlled TrialDouble-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
We assessed the impact of retinoid X receptor (RXR) agonist bexarotene on brain amyloid measured by amyloid imaging in patients with Alzheimer's disease (AD) in a proof-of-concept trial. ⋯ The primary outcome of this trial was negative. The data suggest that bexarotene reduced brain amyloid and increased serum Aβ1-42 in ApoE4 noncarriers. Elevated triglycerides could represent a cardiovascular risk, and bexarotene should not be administered outside a research setting. RXR agonists warrant further investigations as AD therapies.